GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Institutional Ownership

PCI Biotech Holding ASA (OSL:PCIB) Institutional Ownership : 0.55% (As of Jun. 13, 2025)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PCI Biotech Holding ASA's institutional ownership is 0.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PCI Biotech Holding ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PCI Biotech Holding ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


PCI Biotech Holding ASA Institutional Ownership Historical Data

The historical data trend for PCI Biotech Holding ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Institutional Ownership Chart

PCI Biotech Holding ASA Historical Data

The historical data trend for PCI Biotech Holding ASA can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31
Institutional Ownership 0.55 0.55 0.55 0.55 0.55 0.55 0.55 0.55 0.55 0.55

PCI Biotech Holding ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines